Literature DB >> 26405580

Fbxw7 suppresses cancer metastasis by inhibiting niche formation.

Kanae Yumimoto1, Keiichi I Nakayama1.   

Abstract

Fbxw7 has been identified as an oncosuppressor protein in many types of cancer. We have recently shown that loss of Fbxw7 in bone marrow-derived stromal cells (BMSCs) promotes cancer metastasis by increasing production of the chemokine CCL2, which attracts monocytic myeloid-derived suppressor cells (Mo-MDSCs) and macrophages to the metastatic niche.

Entities:  

Keywords:  F-box protein; chemokine; metastasis; niche; ubiquitin ligase

Year:  2015        PMID: 26405580      PMCID: PMC4570111          DOI: 10.1080/2162402X.2015.1022308

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  8 in total

1.  Functional interaction between SEL-10, an F-box protein, and the nuclear form of activated Notch1 receptor.

Authors:  N Gupta-Rossi; O Le Bail; H Gonen; C Brou; F Logeat; E Six; A Ciechanover; A Israël
Journal:  J Biol Chem       Date:  2001-06-25       Impact factor: 5.157

2.  An anti-inflammatory drug, propagermanium, may target GPI-anchored proteins associated with an MCP-1 receptor, CCR2.

Authors:  S Yokochi; H Hashimoto; Y Ishiwata; H Shimokawa; M Haino; Y Terashima; K Matsushima
Journal:  J Interferon Cytokine Res       Date:  2001-06       Impact factor: 2.607

Review 3.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

Review 4.  Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities.

Authors:  Ryan J Davis; Markus Welcker; Bruce E Clurman
Journal:  Cancer Cell       Date:  2014-10-13       Impact factor: 31.743

5.  The Notch intracellular domain is ubiquitinated and negatively regulated by the mammalian Sel-10 homolog.

Authors:  C Oberg; J Li; A Pauley; E Wolf; M Gurney; U Lendahl
Journal:  J Biol Chem       Date:  2001-07-18       Impact factor: 5.157

6.  CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFα.

Authors:  Guangwen Ren; Xin Zhao; Ying Wang; Xin Zhang; Xiaodong Chen; Chunliang Xu; Zeng-rong Yuan; Arthur I Roberts; Liying Zhang; Betty Zheng; Ting Wen; Yanyan Han; Arnold B Rabson; Jay A Tischfield; Changshun Shao; Yufang Shi
Journal:  Cell Stem Cell       Date:  2012-11-15       Impact factor: 24.633

Review 7.  Inflammatory chemokines and metastasis--tracing the accessory.

Authors:  L Borsig; M J Wolf; M Roblek; A Lorentzen; M Heikenwalder
Journal:  Oncogene       Date:  2013-07-15       Impact factor: 9.867

8.  F-box protein FBXW7 inhibits cancer metastasis in a non-cell-autonomous manner.

Authors:  Kanae Yumimoto; Sayuri Akiyoshi; Hiroki Ueo; Yasuaki Sagara; Ichiro Onoyama; Hiroaki Ueo; Shinji Ohno; Masaki Mori; Koshi Mimori; Keiichi I Nakayama
Journal:  J Clin Invest       Date:  2015-01-02       Impact factor: 14.808

  8 in total
  4 in total

Review 1.  Trial Watch: Immunotherapy plus radiation therapy for oncological indications.

Authors:  Erika Vacchelli; Norma Bloy; Fernando Aranda; Aitziber Buqué; Isabelle Cremer; Sandra Demaria; Alexander Eggermont; Silvia Chiara Formenti; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2016-07-25       Impact factor: 8.110

Review 2.  Roles of ubiquitination in the crosstalk between tumors and the tumor microenvironment (Review).

Authors:  Xiuzhen Zhang; Tong Meng; Shuaishuai Cui; Dongwu Liu; Qiuxiang Pang; Ping Wang
Journal:  Int J Oncol       Date:  2022-05-26       Impact factor: 5.884

3.  Upregulation of FBXW7 Suppresses Renal Cancer Metastasis and Epithelial Mesenchymal Transition.

Authors:  Yangke Cai; Meng Zhang; Xiaofu Qiu; Bingwei Wang; Yu Fu; Jun Zeng; Jian Bai; Guosheng Yang
Journal:  Dis Markers       Date:  2017-09-30       Impact factor: 3.434

4.  Phase I dose-escalation trial to repurpose propagermanium, an oral CCL2 inhibitor, in patients with breast cancer.

Authors:  Takaaki Masuda; Miwa Noda; Takahiro Kogawa; Dai Kitagawa; Naoki Hayashi; Takahito Jomori; Yoichi Nakanishi; Keiichi I Nakayama; Shinji Ohno; Koshi Mimori
Journal:  Cancer Sci       Date:  2020-02-11       Impact factor: 6.716

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.